Literature DB >> 24333445

A novel lysophosphatidic acid acyltransferase enzyme (LPAAT4) with a possible role for incorporating docosahexaenoic acid into brain glycerophospholipids.

Miki Eto1, Hideo Shindou2, Takao Shimizu1.   

Abstract

Glycerophospholipids are important components of cellular membranes, required for constructing structural barriers, and for providing precursors of bioactive lipid mediators. Lysophosphatidic acid acyltransferases (LPAATs) are enzymes known to function in the de novo glycerophospholipid biosynthetic pathway (Kennedy pathway), using lysophosphatidic acid (LPA) and acyl-CoA to form phosphatidic acid (PA). Until now, three LPAATs (LPAAT1, 2, and 3) have been reported from the 1-acyl-glycerol-3-phosphate O-acyltransferase (AGPAT) family. In this study, we identified a fourth LPAAT enzyme, LPAAT4, previously known as an uncharacterized enzyme AGPAT4 (LPAATδ), from the AGPAT family. Although LPAAT4 was known to contain AGPAT motifs essential for acyltransferase activities, detailed biochemical properties were unknown. Here, we found that mouse LPAAT4 (mLPAAT4) possesses LPAAT activity with high acyl-CoA specificity for polyunsaturated fatty acyl-CoA, especially docosahexaenoyl-CoA (22:6-CoA, DHA-CoA). mLPAAT4 was distributed in many tissues, with relatively high expression in the brain, rich in docosahexaenoic acid (DHA, 22:6). mLPAAT4 siRNA in a neuronal cell line, Neuro 2A, caused a decrease in LPAAT activity with 22:6-CoA, suggesting that mLPAAT4 functions endogenously. siRNA in Neuro 2A cells caused a decrease in 18:0-22:6 PC, whereas mLPAAT4 overexpression in Chinese hamster ovary (CHO)-K1 cells caused an increase in this species. Although DHA is considered to have many important functions for the brain, the mechanism of its incorporation into glycerophospholipids is unknown. LPAAT4 might have a significant role for maintaining DHA in neural membranes. Identification of LPAAT4 will possibly contribute to understanding the regulation and the biological roles of DHA-containing glycerophospholipids in the brain.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  1-acyl-glycerol-3-phosphate O-acyltransferase; AGPAT; Brain; DHA; DHA-CoA; Docosahexaenoic acid; Glycerophospholipid; LPA; LPAAT; Lysophosphatidic acyltransferase; PA; PC; PE; PS; Phosphatidic acid; docosahexaenoic acid; docosahexaenoyl-CoA; lysophosphatidic acid; lysophosphatidic acid acyltransferase; phosphatidic acid; phosphatidylcholine; phosphatidylethanolamine; phosphatidylserine

Mesh:

Substances:

Year:  2013        PMID: 24333445     DOI: 10.1016/j.bbrc.2013.12.043

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

Review 1.  Phosphatidylserine in the brain: metabolism and function.

Authors:  Hee-Yong Kim; Bill X Huang; Arthur A Spector
Journal:  Prog Lipid Res       Date:  2014-06-30       Impact factor: 16.195

2.  Mice Deficient in lysophosphatidic acid acyltransferase delta (Lpaatδ)/acylglycerophosphate acyltransferase 4 (Agpat4) Have Impaired Learning and Memory.

Authors:  Ryan M Bradley; Emily B Mardian; Darin Bloemberg; Juan J Aristizabal Henao; Andrew S Mitchell; Phillip M Marvyn; Katherine A Moes; Ken D Stark; Joe Quadrilatero; Robin E Duncan
Journal:  Mol Cell Biol       Date:  2017-10-27       Impact factor: 4.272

3.  The fat cell epigenetic signature in post-obese women is characterized by global hypomethylation and differential DNA methylation of adipogenesis genes.

Authors:  I Dahlman; I Sinha; H Gao; D Brodin; A Thorell; M Rydén; D P Andersson; J Henriksson; A Perfilyev; C Ling; K Dahlman-Wright; P Arner
Journal:  Int J Obes (Lond)       Date:  2015-03-18       Impact factor: 5.095

4.  The Agpat4/LPA axis in colorectal cancer cells regulates antitumor responses via p38/p65 signaling in macrophages.

Authors:  Dapeng Zhang; Rongchen Shi; Wei Xiang; Xia Kang; Bo Tang; Chuan Li; Linfeng Gao; Xuan Zhang; Lili Zhang; Rongyang Dai; Hongming Miao
Journal:  Signal Transduct Target Ther       Date:  2020-03-27

5.  PGC-1α-mediated changes in phospholipid profiles of exercise-trained skeletal muscle.

Authors:  Nanami Senoo; Noriyuki Miyoshi; Naoko Goto-Inoue; Kimiko Minami; Ryoji Yoshimura; Akihito Morita; Naoki Sawada; Junichiro Matsuda; Yoshihiro Ogawa; Mitsutoshi Setou; Yasutomi Kamei; Shinji Miura
Journal:  J Lipid Res       Date:  2015-10-05       Impact factor: 5.922

6.  Different mechanisms for selective transport of fatty acids using a single class of lipoprotein in Drosophila.

Authors:  Naoya Matsuo; Kohjiro Nagao; Takuto Suito; Naoto Juni; Utako Kato; Yuji Hara; Masato Umeda
Journal:  J Lipid Res       Date:  2019-05-13       Impact factor: 5.922

7.  A Metabolism-Related Gene Prognostic Index Bridging Metabolic Signatures and Antitumor Immune Cycling in Head and Neck Squamous Cell Carcinoma.

Authors:  Kunpeng Du; Jingwen Zou; Baiyao Wang; Chunshan Liu; Muhammad Khan; Tao Xie; Xiaoting Huang; Piao Shen; Yunhong Tian; Yawei Yuan
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

8.  Higher efficacy of dietary DHA provided as a phospholipid than as a triglyceride for brain DHA accretion in neonatal piglets.

Authors:  Lei Liu; Nana Bartke; Hans Van Daele; Peter Lawrence; Xia Qin; Hui Gyu Park; Kumar Kothapalli; Anthony Windust; Jacques Bindels; Zhe Wang; J Thomas Brenna
Journal:  J Lipid Res       Date:  2014-01-27       Impact factor: 5.922

9.  Plant and algal lysophosphatidic acid acyltransferases increase docosahexaenoic acid accumulation at the sn-2 position of triacylglycerol in transgenic Arabidopsis seed oil.

Authors:  Laura L Wayne; Daniel J Gachotte; Paul R Graupner; Yelena Adelfinskaya; David G McCaskill; James G Metz; Ross Zirkle; Terence A Walsh
Journal:  PLoS One       Date:  2021-08-25       Impact factor: 3.240

Review 10.  Disorders of phospholipid metabolism: an emerging class of mitochondrial disease due to defects in nuclear genes.

Authors:  Ya-Wen Lu; Steven M Claypool
Journal:  Front Genet       Date:  2015-02-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.